Doxazosin Mesylate: Midas Pharma received Sister-CEP approval

We are thrilled to announce that we have received a Sister-CEP approval from the EDQM for Doxazosin Mesylate (Midas Own IP).

This marks the first regulatory procedure for applying for a Sister-CEP for our company, Midas Pharma GmbH.

Through this achievement, we have been able to quickly and effectively enhance the supply chain for the production of our API and significantly improving the cost structure for the manufacturing of the active ingredient as well. This milestone underscores our commitment to quality, efficiency and supply chain security in pharmaceutical production